Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals, Inc., and Astellas Pharma Inc. today announced that a Phase 3 trial evaluating the efficacy and safety of the addition of Tarceva (erlotinib) tablets to Nexavar (sorafenib) tablets did not improve overall survival for patients with unresectable hepatocellular carcinoma (HCC) vs. Nexavar alone.

23 Jul 2012

Researchers link specific gene mutations with four recognized subtypes of medulloblastoma

Researchers at Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) and several collaborating institutions have linked mutations in specific genes to each of the four recognized subtypes of medulloblastoma, the most common malignant brain tumor of children. The discovery, reported July in the journal Nature, provides doctors with potential biomarkers for guiding and individualizing treatment and reveals prospective therapeutic opportunities for countering this devastating malignancy.

23 Jul 2012

'Medical travel' can be used to access advanced technologies

The search for medical technologies through 'medical travel' can change the lives of patients and their family members, according to medical anthropologists Cecilia Vindrola-Padros and Linda M. Whiteford, who examined the lives of Bolivian and Paraguayan families who traveled to Buenos Aries, Argentina, seeking pediatric oncology care for their children.

21 Jul 2012

Kyprolis for multiple myeloma receives FDA approval under accelerated approval program

The U.S. Food and Drug Administration today approved Kyprolis (carfilzomib) to treat patients with multiple myeloma who have received at least two prior therapies, including treatment with Velcade (bortezomib) and an immunomodulatory therapy. A form of blood cancer that arises from plasma cells, multiple myeloma usually grows in bone marrow, the soft, spongy tissue found inside most bones.

21 Jul 2012

EMA CHMP issues positive opinion for conditional approval of brentuximab vedotin for lymphoma

Millennium: The Takeda Oncology Company and, Takeda Pharmaceutical Company Limited today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for conditional approval of brentuximab vedotin for two indications.

21 Jul 2012

Janssen-Cilag receives positive opinion from EMA CHMP for DACOGEN

Janssen-Cilag International NV announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of DACOGEN (decitabine) for Injection.

21 Jul 2012

Researchers discover reason why breast cancer cells become drug resistant

Breast cancer treatments such as Herceptin that target a marker called HER2 have dramatically improved outcomes for women with this type of cancer. But nearly half of these cancers are resistant to Herceptin from the start and almost all of them will eventually become resistant.

21 Jul 2012

Pfizer receives positive opinion from EMA CHMP for crizotinib to treat ALK-positive NSCLC

Pfizer announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that crizotinib be granted conditional marketing authorization in the European Union (EU), for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

21 Jul 2012

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

Novartis receives FDA approval for Afinitor to treat HER2-negative breast cancer

The U.S. Food and Drug Administration today approved Afinitor (everolimus) for use in combination with Aromasin (exemestane) to treat certain postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer.

21 Jul 2012

Mechanism of CSF drainage benefits unclear in normal pressure hydrocephalus

The beneficial effect of removing cerebrospinal fluid from patients with normal pressure hydrocephalus is not mediated by reduction of ventricle volume, research suggests.

20 Jul 2012

Breast-conserving surgery carries high reoperation risk

Women who undergo breast-conserving surgery for breast cancer may be at an increased risk for reoperation, research suggests.

20 Jul 2012

Risk factors defined for retinal detachment after cataract surgery

Study results spanning 22 years show that the risk for retinal detachment after undergoing phacoemulsification for cataracts has fallen dramatically, but that younger, and male patients are more at risk for this adverse outcome than their older, female peers.

20 Jul 2012

Moderate alcohol consumption may reduce risk of kidney cancer

A majority of previous epidemiologic studies have shown that moderate drinking is associated with a lower risk of kidney cancer, which may affect about 1% of the general population. In published prospective cohort studies, the risk for such cancer among moderate drinkers is usually about 25% less than the risk seen among non-drinkers.

20 Jul 2012

HealthHIV, CCO announce new series of CME/CE-certified interactive local live workshops

Clinical Care Options (CCO), a leader in next-generation medical education, information, and publishing for healthcare professionals, announces a new series of CME/CE-certified interactive local live workshops developed and implemented in partnership with HealthHIV, the leading national HIV nonprofit organization building the capacity of primary care providers to integrate HIV care into their practices.

20 Jul 2012

Teva contributes $2.5M to The Franklin Institute for development of neuroscience exhibit

The Franklin Institute has received a $2.5 million contribution from leading global pharmaceutical company Teva Pharmaceuticals to develop a signature innovative exhibit at the museum exploring neuroscience and the human brain, entitled Your Brain. This contribution brings The Franklin Institute's Inspire Science fundraising campaign total to $65 million.

20 Jul 2012

Conatus, University of Alberta initiate islet cell transplant Phase I/II trial of emricasan for diabetes

Conatus Pharmaceuticals Inc. and the University of Alberta announced today the treatment of the first patient in an investigator-initiated islet cell transplant Phase I/II trial of emricasan (IDN-6556), a pan-caspase inhibitor.

20 Jul 2012

IMDx HSV-1/2 for Abbott m2000 assay receives CE-marking

IntelligentMDx (IMDx) announced today that it has obtained CE-marking for its fourth automated, high-throughput molecular test designed and developed for the Abbott m2000 System.

20 Jul 2012

BioAlliance Pharma, Vestiq enter license agreement for Oravig to treat oropharyngeal candidiasis

BioAlliance Pharma SA, an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces it has signed a binding term sheet with Vestiq for the commercialization rights in the United States of Oravig (known as Loramyc in Europe) for the treatment of oropharyngeal candidiasis in adults.

20 Jul 2012

Patients, partners affected by colorectal cancer course

Partners of individuals with colorectal cancer, as well as the patients themselves, are at risk for psychologic morbidity according to the type of treatment given, show Portuguese study results.

19 Jul 2012

Oncology News and Research

Further Reading

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Researchers link specific gene mutations with four recognized subtypes of medulloblastoma

'Medical travel' can be used to access advanced technologies

Kyprolis for multiple myeloma receives FDA approval under accelerated approval program

EMA CHMP issues positive opinion for conditional approval of brentuximab vedotin for lymphoma

Janssen-Cilag receives positive opinion from EMA CHMP for DACOGEN

Researchers discover reason why breast cancer cells become drug resistant

Pfizer receives positive opinion from EMA CHMP for crizotinib to treat ALK-positive NSCLC

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Novartis receives FDA approval for Afinitor to treat HER2-negative breast cancer

Mechanism of CSF drainage benefits unclear in normal pressure hydrocephalus

Breast-conserving surgery carries high reoperation risk

Risk factors defined for retinal detachment after cataract surgery

Moderate alcohol consumption may reduce risk of kidney cancer

HealthHIV, CCO announce new series of CME/CE-certified interactive local live workshops

Teva contributes $2.5M to The Franklin Institute for development of neuroscience exhibit

Conatus, University of Alberta initiate islet cell transplant Phase I/II trial of emricasan for diabetes

IMDx HSV-1/2 for Abbott m2000 assay receives CE-marking

BioAlliance Pharma, Vestiq enter license agreement for Oravig to treat oropharyngeal candidiasis

Patients, partners affected by colorectal cancer course

Event guide: The 9th DDR Inhibitors Summit 2026 eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News